

Statistics on the participants in training events on vectors technology and gene therapy since 2001

Short title of the event:		GVPN ⁽¹⁾ CONFERENCE		1 st EUROLABCOURSE ⁽²⁾				2 nd EUROLABCOURSE				3 rd EUROLABCOURSE				MOLEDA SUMMER SCHOOL ⁽³⁾				CONCERT LABCOURSE ⁽⁴⁾			
Dates:		4-5/10/2001		14-27/04/ 2002				1-14 /02/ 2004				14-26/ 06/ 2004				15-22/ 09/ 2007				29/06-05/07/ 2008			
Place:		EVRY, France		EVRY				BELLATERRA, Spain				EVRY				EVRY/MALFORT/PARIS				EVRY			
PARTICIPANTS		TOTAL		TOTAL		PC		TOTAL		PC		TOTAL		PC		TOTAL		PC		TOTAL		PC	
Country of the pts	nb	%	nb	%	nb	%	nb	%	nb	%	nb	%	nb	%	nb	%	nb	%	nb	%	nb	%	
1. Algeria																							
2. Australia																							
3. Austria	1	0,4	1	1			3	2,0			1	0,6					2	1,2	1	3,3			
4. Belgium	13	4,6	10	7			1	0,7			2	1,2			2	2,7	8	4,7	2	6,6			
5. Brazil																							
6. Bulgaria							1	0,7	1	3,1			1	3,1					1	0,6			
7. Canada			1	1			2	1,3	1	3,1			2	1,2					2	1,2	2	6,6	
8. China	1	0,4					2	1,3	1	3,1			1	0,6	1	3,1			1	0,6			
9. Czech Republic							1	0,7											1	0,6			
10. Denmark			3	2			1	0,7															
11. Finland											1	0,6	1	3,1					2	1,2			
12. France	223	79,4	42	30	8	25	45	29,6	4	12,5	64	38	4	12,5	45	60,0	5	25,0	94	55,0	8	26,7	
13. Germany	8	2,9	17	12	2	6,3	3	2,0			8	4,8	1	3,1	3	4,0	1	5,0	9	5,3			
14. Greece							2	1,3	1	3,1			1	0,6	1	3,1							
15. Hungary			2	1	2	6,3	5	3,3	3	9,4			6	3,6	1	3,1							
16. Iceland							1	0,7	1	3,1													
17. Iran							1	0,7					1	0,6	1	3,1							
18. Ireland											3	1,8	1	3,1					1	1,2	1	3,3	
19. Israel	4	1,4	2	1	1	3,1					3	1,8	2	6,3	4	5,3	1	5,0	2	1,2	1	3,3	
20. Italy	4	1,4	6	4	2	6,3	3	2,0	2	6,3	14	8,4	5	15,6	3	4,0	2	10,0	7	4,1			
21. Japan							2	1,3			1	0,6	1	3,1									
22. Korea			1	1			1	0,7															
23. Latvia			1	1																			
24. Lithuania			2	1	1	3,1	2	1,3	2	6,3					2	2,7	2	10,0	2	1,2			
25. Luxembourg			1	1																			
26. Mexico							1	0,7															
27. Netherlands	3	1,1	6	4	1	3,1	3	2,0	1	3,1	5	3			1	1,3			4	2,3	1	3,3	
28. Norway															1	1,3							
29. Poland							1	0,7	1	3,1	1	0,6	1	3,1	1	1,3	1	5,0	1	0,6			
30. Portugal			1	1	1	3,1	4	2,6	2	6,3	2	1,2	1	3,1	1	1,3	1	5,0	4	2,3	2	6,6	
31. Romania			1	1	1	3,1									1	1,3	1	5,0	5	2,9	4	13,2	
32. Russia							1	0,7	1	3,1	1	0,6			1	1,3	1	5,0	1	0,6			
33. Slovenia											1	0,6											
34. Spain	5	1,8	7	5	7	21,9	46	30,3	6	18,8	10	6	4	12,5	2	2,7	2	10,0	6	3,5	2	6,6	
35. Sweden	2	0,7	11	8	4	12,5	3	2,0	1	3,1	3	1,8							1	0,6			
36. Switzerland	3	1,1	5	4	1	3,1	3	2,0			6	3,6	1	3,1					2	1,2			
37. Taiwan											1	0,6											
38. Turkey			1	1			2	1,3	3	9,4	7	4,2	3	9,4					2	1,2	1	3,3	
39. United Kingdom	12	4,3	12	9	1	3,1	5	3,3			10	6			5	6,7	1	5,0	5	2,9	1	3,3	
40. Uruguay							1	0,7	1	3,1													
41. USA	2	0,7	7	5			6	4,0			8	4,8	2	6,3	1	1,3			10	5,8	4	13,	
Total participants	281	100	140	100	32	100	152	100	32	100	167	100	32	100	75	100	20	100	171	100	30	100	
Nb of countries	13		22		13		29		18		29		18		16		12		23		13		
% of women	45		44		75		49,5		50		39		65		51		55		55		70		
nb of institutions	131		87				73				101				42				77				
Academic body, industries⁽⁵⁾, others⁽⁶⁾	105 acad., 22 ind., 4 others		(53 acad., 29 ind., 5 others)				70 acad., 3 industries				74 acad., 25 ind., 2 others				38 acad., 5 ind., 1 other				59 acad., 18 industries				
Sponsors	EC, AFM, Industries		EC, AFM, INSERM, GENOPOLE, EMBO, Industries				EC, FEBS, INSERM, GENOPOLE, Industries				EC, GENOPOLE, CG-Essonne, INSERM, Industries				IdF, AFM, CLINIGENE EC project				CONCERT EC project, IdF, AFM, GENOPOLE, INSERM, Industries				

Legend: (1) Gene Vector Production Network, a vector production service involving several AFM-funded laboratories to provide vectors for the scientific community from 1997 to 2002. About 3000 batches of viral vectors and other gene transfer reagents were distributed to more than 300 teams in France and abroad. The GVPN conference was the first training event on gene transfer and therapy as well as the assessment of the progress achieved with the vectors provided by the GVPN in the research projects. **(2)** The Eurolabcourses (ELC) were courses with a new format involving a symposium open to a large number of scientists and professionals from all institutions and a practical course (PC) restricted to selected students and young researchers. The full titles of the three courses in 2002 and 2004 were: the 1st ELC, *First multidisciplinary theoretical and practical training in Vectorology*, was on the basic biology and technology of all non-viral and viral (AAV, AdV, MLV and LVV) vectors. The 2nd ELC, *Towards clinical gene therapy: pre-clinical gene transfer assessment*, focused the methods of *in vivo* gene transfer by using viral vectors (AAV and AdV) into mice and rat tissues (brain, muscle, liver and lung). The 3rd ELC, *Advanced Methods for Industrial Production, Purification and Characterisation of Gene Vectors*, was on the most recent techniques of AAV, AdV and LVV. **(3)** MOLEDA was a 6th FP project funded by the European Commission focused on research projects using non-viral vectors. The full title of the course was *Non-viral gene transfer into muscle and skin*. For more information (scientific program, final report etc...) see www.easco.org. **(4)** CONCERT is a 6th FP project funded by the European Commission focused on gene therapy of genetic disease with RV and LVV vectors. The full title of the course was *Lentiviral vectors: concepts, practice hope and reality*. See more information at the web site www.consertlabcourse.easco.org. **(5)** The industries participation is intended either as the participants' employer institution or sponsor institution, or both. **(6)** Patient's associations, ethical/regulatory agencies, scientific press.